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Abstract
Background: Locally advanced (pT3-4N0M0) hepatocellular carcinoma (HCC) is a heterogeneous group of tumors,
which consists of four different categories, including HCC with “multiple tumors more than 5 cm”, “major vascular
invasion”, “invasion of adjacent organs”, and “perforation of visceral peritoneum”. The aim of our study was to verify
whether the 2002 version of the Tumor-Node-Metastasis staging system could predict surgical outcomes in
patients with locally advanced HCC.
Methods: We retrospectively reviewed 298 patients with pT3-4N0M0 HCC who underwent hepatic resection from
1993 to 2000 in an academic tertiary hospital. Overall survival (OS) and cumulative recurrence rate (CRR) of the four
categories of locally advanced HCC patients were compared.
Results: In multivariate analysis, major vascular invasion was identified as the most significant factor (HR = 3.291,
95% CI 2.362-4.584, P < 0.001) followed by cirrhosis status on OS, and was found to be the only independent
factor of CRR (HR = 2.242, 95% CI 1.811-3.358, P < 0.001) in patients with locally advanced HCC. Among the four
categories of locally advanced HCC, OS was significantly worse, and CRR was significantly higher in patients with
HCC with major vascular invasion (pT3) than with multiple tumors more than 5 cm (pT3); or tumor invasion of
adjacent organs (pT4); or perforation of visceral peritoneum (pT4). No significant differences were observed in OS
or CRR between the latter three groups of patients.
Conclusions: HCC with major vascular invasion, which are classified as pT3 under the current TNM staging, have
the worst prognosis when compared with the other categories of pT3-4 disease. There is a need to redefine the T
classification and to stratify locally advanced HCC.
Background
Hepatocellular carcinoma (HCC) is one of the most
common malignant tumors in the world with a globally
increasing annual incidence [1,2]. For accurate prognos-
tic assessment after partial hepatectomy and patient
selection for adjuvant therapy, the pathologic tumor-
node-metastasis (pTNM) staging system has traditionally
been used. This TNM staging system has the advantages
of a more detailed T classification than in any other sta-
ging systems [3]. However, the current 2002 TNM sta-
ging system is not completely satisfactory. The
stratification and the prognostic classification of
advanced T stages of HCC are most debatable [4-7].
In the 2002 version of the TNM staging system,
locally advanced HCC consists of four categories of dis-
eases, with pT3 being classified as multiple tumors more
than 5 cm; or tumors with tumor thrombus within the
major branch of portal or hepatic veins, and pT4 being
classified as tumors with direct invasion of adjacent
organs other than gallbladder; or perforation of visceral
peritoneum [8,9]. Although major vascular invasion has
been recognized as a very strong predictive factor of dis-
mal prognosis, [6,7] and several studies have also shown
invasion of adjacent organs or perforation of visceral
peritoneum was not definitely associated with a worse
survival, [10,11] HCC with invasion of adjacent organs
or perforation of visceral peritoneum but not major
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vascular invasion are classified as pT4 in the current
2002 TNM staging system. These published data
strongly suggest HCC in advanced T stages are not clas-
sified appropriately under the current TNM
classification.
In this study, we retrospectively analyzed the prospec-
tively collected data of 298 patients with pT3-4N0M0
HCC who underwent partial hepatectomy to analyze the
ability of the current TNM staging system to predict
survival. Overall survival (OS) and cumulative recur-
rence rate (CRR) of the four categories of locally
advanced HCC patients were also compared.
Methods
Patients
Between January 1993 and December 2000, 890 patients
underwent hepatic resection for HCC with curative
intent, which was defined as macroscopically complete
tumor resection at Sun Yat-sen University Cancer Cen-
ter. Three hundred and five (34.3%) patients were classi-
fied as locally advanced stages (pT3-4N0M0) according
to the 2002 version of American Joint Committee on
Cancer (AJCC)/International Union Against Cancer
(UICC) TNM staging system [8,9]. Seven patients who
died within 30 days of operation were excluded, leaving
298 patients for the analyses.
Preoperative liver functional reserve was assessed by
blood biochemistry, Child-Pugh grading, and indocyanine
green retention rate at 15 minutes (ICGR15). Only Child-
Pugh A patients were offered major hepatic resection,
which was defined as the resection of three or more
Couinaud’s liver segments. In selected Child-Pugh B
patients, minor hepatectomy, defined as resection of two
or fewer liver segments, was carried out. MELD score
was also calculated using pre-operative values of three
laboratory tests: INR for prothrombin time, serum total
bilirubin and serum creatinine [12]. In our daily practice,
the “surgical margin” examination procedure is as fol-
lows: the marginal liver tissues taken from the “tumor
bed” in the residual liver were used for pathologic review
to examine whether it is tumor-free. Both parenchymal
involvement of the margin and vascular permeation at
the margin were considered as “microscopic positive
margin” (which means R1 resection). In the present
study, all the tumors had been macroscopically comple-
tely resected with a microscopically tumor-free margin
proven by the pathologists (which means R0 resection).
We define those with an obvious margin as “margin > 0
mm”, and the others whose tumor was resected along
with the edge of the tumor without an obvious margin
but microscopically also with a tumor-free margin as
“margin = 0 mm”. Tumors with involvement of the ipsi-
lateral branch of the portal or hepatic veins or invasion
of adjacent organs were considered resectable provided
that en-bloc resection of the entire tumor could be per-
formed with a tumor-free margin. Multiple tumors in
more than one hemilivers were resected using extended
right or left hepatectomy in patients with adequate hepa-
tic functional reserve (Child-Pugh A and ICGR15 ≤ 10%);
otherwise, separate minor hepatectomy of the tumors in
the 2 hemilivers were performed.
Histological diagnosis of HCC was reconfirmed by
review of pathologic slides. Tumor grade was assessed
using the nuclear grading scheme as outlined by
Edmondson and Steiner. Tumor size was based on the
largest diameter of the tumor in the resected specimen.
The number of HCCs was defined by the total number
of nodules, including intrahepatic metastasis. Major vas-
cular invasion was defined as gross invasion of the trunk
or the main branches of the portal or hepatic veins.
Invasion of adjacent organs was defined as gross inva-
sion of an adjacent organ other than the gallbladder
which was resected en-bloc with the liver tumor. Per-
foration into visceral peritoneum was based on gross
and histological study of the visceral peritoneum.
This study is a retrospective study of a prospectively
collected database. All clinicopathological data were col-
lected at the patient’s presentation and at follow-up vis-
its until the patient died or lost to follow-up. We
regularly updated the database especially for tumor
recurrence and survival status. This study was approved
by the Clinical Research Ethics Committee of Sun Yat-
sen University Cancer Center and conformed to the
ethical guidelines of the 1975 Declaration of Helsinki
and the current ethical guidelines. Written informed
consent for examination and treatment was obtained
from each patient.
Follow-up
This study was censored on June 30, 2009. The median
follow-up was 37 months, (range from 2 to 146
months). At each follow-up visit, we carried out a com-
plete clinical examination of the patient. Serum alpha-
fetoprotein (AFP), abdomen ultrasonography and chest
x-ray were carried out once every 1-3 monthly in the
first year, and once every 3-6 monthly thereafter. When
tumor recurrence was suspected, computed tomography
and/or magnetic resonance imaging and/or positron
emission tomography were done. Whenever possible,
salvage treatments were given to patients with recur-
rence or metastases. The treatments included re-resec-
tion, transarterial chemoembolization, radiofrequency
ablation, percutaneous ethanol injection and systemic
chemotherapy.
Statistical Analysis
Continuous data were expressed as either mean ± S.D.
or medians (range), where appropriate. Chi-square or
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Fisher’s exact test was used to compare the difference of
categorical variables. The primary endpoints were over-
all survival (OS) and cumulative recurrence rates (CRR).
OS was defined as the interval from curative surgery to
the date of death or the date of last contact if the
patient was still alive. Time to tumor recurrence was
defined as the interval from surgery to the date when
tumor recurrence or metastasis was diagnosed. The sur-
vival curves were calculated by the Kaplan-Meier
method and compared using the log-rank test. Signifi-
cant prognostic factors on univariate analysis were
entered into a multivariate analysis using the Cox pro-
portional hazards model. A p-value < 0.05 was consid-
ered as significant. Statistical procedures were
performed using the SPSS software package (Version
15.0; SPSS Inc., Chicago, IL).
Results
Demographic and Clinicopathological Data
The demographic and clinicopathological characteristics
of the 298 patients with locally advanced HCC in this
study are listed in Table 1. In 16 patients, TACE was
given followed by hepatic resection after shrinkage of
the tumor, and in 76 patients postoperative adjuvant
TACE was given. At the time this study was censored,
tumor recurrence was diagnosed in 271 patients (90.9%),
and 253 patients (84.9%) had died. For the 271 patients
with recurrence, 249 patients had intrahepatic recur-
rence, 15 had both intrahepatic and extrahepatic recur-
rences, and 7 had extrahepatic recurrence. The 3-year/
5-year OS and CRR of the total cohort after hepatic
resection were 28.2%/16.9% and 85.7%/90.8%,
respectively.
Prognostic Factors for Survival and Recurrence
Among the 24 clinicopathological factors analyzed by
univariate log-rank analysis, only albumin (ALB) level
(P = 0.004), cirrhosis status (P = 0.028) and major vas-
cular invasion (P < 0.001) were identified as poor prog-
nostic factors for OS (Table 2). The significant
prognostic factors found on univariate analysis were
further tested in the multivariate Cox model. Major vas-
cular invasion was found to be the most significant fac-
tor (HR = 3.291, 95% CI 2.362-4.584, P < 0.001),
followed by cirrhosis status (HR = 1.400, 95% CI 1.010-
1.941, P = 0.044). (Table 3)
When the same factors in Tables 2 were analyzed for
their prognostic influence on cumulative recurrence
rate, only ALB level (P = 0.002) and major vascular
invasion (P < 0.001) were significant factors in the uni-
variate analysis. The 1-year/3-year CRRs of 61 patients
with major vascular invasion were 85.2%/100.0%,
whereas the corresponding CRRs of 237 patients with-
out major vascular invasion were 54.7%/80.2%,
respectively. In multivariate analysis, major vascular
invasion was the only significant predictive factor of
CRR (HR = 2.242, 95% CI = 1.811-3.358, P < 0.001).
(Table 3)
The Impact of Major Vascular Invasion in Stage pT3/
4N0M0 HCC
To further verify the grave impact of major vascular
invasion on overall survival and recurrence risk in stage
pT3/4N0M0 HCC at presentation, we selected patients
in whom the four pathologic features were present sin-
gularly, and classified them into four subgroups: “Major
vascular invasion (n = 21)” as Gp1, “Multiple tumors
more than 5 cm (n = 108)” as Gp2, “Invasion of adja-
cent organs (n = 32)” as Gp3, and “Perforation of visc-
eral peritoneum (n = 57)” as Gp4. Comparisons of
clinicopathological data of the four subgroups of
patients with pT3/4N0M0 HCC are depicted in Table 1.
The four groups were not significantly different in liver
function parameters and tumor histological features,
except that there was a significantly higher proportion
of microvascular invasion in tumors with major vascular
invasion than the other three groups. Serum AFP levels
were also significantly higher in patients with major vas-
cular invasion compared with the other three groups.
Intraoperative blood loss, the proportion of patients
requiring blood transfusion, and the proportion of
patients receiving preoperative and postoperative TACE
were all similar.
As shown in Figure 1A, the OS of Gp1 (median 5.8
months) was significantly worse than Gp2 (median 21.7
months, P < 0.001), Gp3 (median 17.3 months, P <
0.001) and Gp4 (median 19.5 months, P = 0.001). Simi-
larly, the 3-year CRR of Gp1 (100%) was significantly
higher than Gp2 (79.9%, P < 0.001), Gp3 (85.5%, P =
0.006) and Gp4 (84.2%, P = 0.001) (Figure 1B). There
were no significant differences in OS or in CRR between
the latter three subgroups (P > 0.05).
To evaluate whether concomitant major vascular inva-
sion influenced survival of patients with other patholo-
gic features, we identified the following three
subgroups: “patients with multiple tumors more than 5
cm and major vascular invasion” as Gp5 (n = 17),
“patients with invasion of adjacent organs and major
vascular invasion” as Gp6 (n = 10), and “patients with
perforation of visceral peritoneum and major vascular
invasion” as Gp7 (n = 13). Median survivals of Gp5,
Gp6 and Gp7 were 7.6 months, 5.7 months and
4.3 months, respectively, while the 3-year CRR of which
was all 100%. The OS and CRR of Gp5, Gp6 and Gp7
were compared with Gp1 (major vascular invasion, n =
21). Results showed that there were no significant dif-
ferences of OS (Figure 2A) or CRR (Figure 2B) among
these four subgroups (P > 0.05).
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Recurrence Type in Four Groups of Locally Advanced HCC
Since recurrence is the main cause of death after cura-
tive partial hepatectomy for HCC, we evaluated the dif-
ference in recurrence type for the four categories of
locally advanced HCC (Gp1-4). We classified tumor
recurrence into early or late with 12 months as the cut-
off point, [13,14] and the number of recurrent nodules
into single or multiple recurrence. As shown in Table 4,
early recurrence occurred in 90.5% of Gp1, which was
significant higher than Gp2, Gp3 and Gp4 (P = 0.006,
0.041 and 0.024, respectively). Multiple recurrence was
observed in 85.7% of Gp1, which was also significantly
higher than Gp3 and Gp4 (P = 0.039 and 0.036,
respectively).
Discussion
To provide a better prognostic prediction for cancer
patients, the AJCC/UICC TNM staging system has been
updated periodically based on new evidence from clinical
studies [15]. In 2002, the TNM staging system for HCC
was revised and it put more emphasis on vascular inva-
sion. However, patients with major vascular invasion are
still classified as pT3 after this revision. Many studies
have shown HCC with major vascular invasion had extre-
mely poor outcomes, [6,7] but HCC with invasion of
adjacent organs or perforation of visceral peritoneum
were not definitely associated with such a poor prognosis
[10,11]. Thus, there is a need to reassess the accuracy of
the current TNM classification for pT3-4 tumors.




invasion (n = 21)
Multiple tumors more than
5 cm (n = 108)
Invasion of adjacent
organs (n = 32)
Perforation of visceral
peritoneum (n = 57)
Gender, Male:
Female
276:22 20:1 100:8 30:2 51:6
Age (years) 48.0 ± 10.7 48.4 ± 12.5 46.1 ± 10.6 49.0 ± 8.2 45.6 ± 10.1
HBsAg positive 257 (86.2%) 17(81.0%) 85(78.7%) 26(81.3%) 51(89.5%)
HCVAb positive 18 (6.0%) 1(4.8%) 3(2.8%) 2(6.3%) 3(5.3%)
ALB (g/L) 42.7 ± 5.4 40.0 ± 4.8 43.1 ± 5.1 39.7 ± 5.7 43.4 ± 5.2
TBIL (μmol/L) 17.0 ± 9.5 18.0 ± 10.9 16.4 ± 9.6 17.6 ± 10.1 16.6 ± 5.9
PT (s) 13.6 ± 1.8 13.9 ± 2.5 13.6 ± 1.9 14.2 ± 2.1 13.0 ± 1.9
ICGR15 (%) 11.1 ± 6.4 12.9 ± 6.8 10.0 ± 5.6 10.3 ± 4.3 8.2 ± 2.8
AFP (μg/L)
median (range) †
488 (1-332318) 2839(76-46135) 487(1-332318) 151.5(2-32318) 817(2-266360)
Child-Pugh A 260 (87.6%) 19(90.5%) 97(89.8%) 27(84.4%) 48(84.2%)
MELD score
median (range)
7 (6-14) 7(6-9) 7(6-14) 7(6-11) 7(6-10)
Cirrhosis 241 (80.9%) 17(80.9%) 89(82.4%) 26(81.3%) 45(78.9%)
Tumor size (cm) 9.7 ± 3.8 8.6 ± 2.70 9.1 ± 3.0 10.9 ± 3.5 8.8 ± 2.8
Tumor
encapsulation
87 (29.2%) 5(23.8%) 36(33.3%) 8(25.0%) 14(24.6%)
Microvascular
invasion‡
187 (62.8%) 21(100%) 51(47.2%) 20(62.5%) 32(56.1%)
Resection margin
> 0 mm
110 (36.9%) 6(28.6%) 39(36.1%) 12(37.5%) 19(33.3%)
Major hepatic
resection
217 (72.8%) 16(76.2%) 81(75%) 21(65.6%) 38(66.7%)
Blood loss, liters 0.8 ± 0.5 0.9 ± 0.4 0.8 ± 0.6 0.7 ± 0.4 0.8 ± 0.7
Blood transfusion 157 (52.7%) 14(66.7%) 57(53.3%) 22(68.7%) 36(63.2%)
Previous TACE 16 (5.4%) 1(3.1%) 5(4.6%) 2(6.3%) 2(3.5%)
Postoperative
adjuvant TACE
76 (25.5%) 6(28.6%) 32(33.3%) 7(21.9%) 9(15.8%)
Unless otherwise stated, continuous data are expressed as mean ± SD; other figures indicate number of patients.
HBsAg, hepatitis B surface antigen; HCVAb, hepatitis C virus antibody; ALB, albumin; TBIL, total bilirubin; PT, prothrombin time; ICGR15, indocyanine green
retention rate at 15 minutes; AFP, a-fetoprotein; MELD, model for end-stage liver disease; TACE, transarterial chemoembolization.
* The four subgroups were selected patients in whom the four pathologic features present singularly.
† Serum AFP levels of patients with major vascular invasion were significantly higher than those of the other three subgroups (P < 0.05).
‡ The proportion of patients with microvascular invasion was significantly higher in patients with major vascular invasion than in the other three subgroups (P <
0.05).
There were no significant differences between any groups in any other parameters.
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The issue whether HCC with major vascular invasion
is correctly classified was first raised by Poon et al. In
their series, patients with major vascular invasion had
significantly worse long-term survival compared with
the other three categories of stage IVA HCC in the pre-
vious version of the TNM classification [7]. In a multi-
center study which was the basis of the current TNM
staging system, Vauthey et al also showed that the survi-
val of patients with multiple bilobar tumors or invasion
of adjacent organs was better than patients with tumors
with major vascular invasion [6]. However, a major lim-
itation of their study is that the number of patients with
invasion of adjacent organs was relatively small (n = 11,
or 2% of the total cohort). Thus, AJCC/UICC decided
not to change the definition of pT4 for the 2002 version
of the TNM classification. In our present study, major
vascular invasion showed the strongest impact on prog-
nosis both in univariate and multivariate analyses.










Female 22 45.5 31.8 18.2
Male 276 59.1 25.9 15.9
Age (years) 0.079
≤48 146 54.7 22.9 13.7
>48 152 60.5 29.6 18.3
HBsAg 0.269
Negative 41 58.7 37.6 18.8
Positive 257 56.5 23.2 14.9
HCVAb 0.380
Negative 280 55.2 27.3 18.2
Positive 18 47.5 22.0 12.9
ALB (g/L) 0.004
≤35 37 42.3 7.7 0.0
>35 261 59.6 27.7 17.3
TBIL (μmol/L) 0.879
≤20 204 62.8 29.3 16.0
>20 94 58.0 28.0 14.3
PT (s) 0.185
≤13.5 148 62.0 32.9 22.3
>13.5 150 57.0 24.6 14.4
ICGR15 (%) 0.423
≤10 155 52.2 26.7 17.8
>10 143 61.7 28.2 19.4
AFP (μg/L) 0.112
≤25 48 63.2 34.3 20.5
>25 250 56.0 25.8 16.0
Child-Pugh 0.275
A 260 59.4 27.4 16.5
B 38 50.0 18.8 12.5
MELD 0.243
≤7 169 58.0 24.7 13.9
>7 129 57.2 32.6 20.7
Cirrhosis 0.028
No 57 61.0 39.5 26.6
Yes 241 57.8 23.5 13.8
Tumor size(cm) 0.278
≤5 35 66.0 31.0 21.0









Solitary 108 59.7 33.3 23.3
Multiple 190 57.8 23.1 12.5
Tumor location 0.126
Unilobar 255 52.7 27.2 17.3
Bilobar 43 45.2 21.4 10.0
Tumor encapsulation 0.093
Yes 87 54.1 26.1 18.1
No 211 44.1 17.0 12.0
Table 2: Univariate analysis of prognostic factors by log-
rank test (Continued)
Microvascular invasion 0.117
No 111 56.5 24.0 16.7
Yes 187 48.1 19.4 11.0
Major vascular invasion <0.001
No 237 65.2 32.2 19.6




No 219 59.9 27.7 16.0




No 220 60.1 26.9 18.4
Yes 78 53.8 21.0 13.6
Resection margin(mm) 0.201
0 188 49.3 20.8 12.7
>0 110 58.4 26.1 17.9
Resection extent 0.062
Major 217 54.7 23.5 15.2
Minor 81 67.9 28.0 18.9
Blood loss(L) 0.140
≤0.8 163 62.8 30.5 21.5
>0.8 135 52.9 21.2 12.9
Blood transfusion 0.488
No 142 59.0 26.3 17.6
Yes 157 57.9 26.6 14.4
Previous TACE 0.724
No 282 57.3 27.1 16.4




No 222 61.7 28.6 15.5
Yes 76 53.2 23.0 15.2
Li et al. BMC Cancer 2010, 10:535
http://www.biomedcentral.com/1471-2407/10/535
Page 5 of 9
Furthermore, applying the criteria used in the 2002
TNM classification, patients with HCC with major vas-
cular invasion (pT3) in our study had worse survival
and more recurrence than HCC with invasion of adja-
cent organs or perforation of visceral peritoneum (pT4)
or multiple tumors more than 5 cm (pT3). Moreover,
for patients who had major vascular invasion combined
with any of the other three locally advanced pathologic
features, the prognosis was similar to patients with HCC
with major vascular invasion only. Our results indicated
that once major vascular invasion occurred, prognosis
became so poor that it was regardless of the presence or
absence of any other tumor characteristics. Our data
showed there is a need to redefine the T classification
and to put more emphasize on major vascular invasion
because of its overwhelmingly adverse prognostic
influence.
It has also been widely accepted that major vascular
invasion indicates advanced HCC with a high risk of
recurrence, which is the main cause of death for HCC
patients after surgical resection [14,16,17]. In the present
study, tumor recurrence was observed in all patients
with HCC with major vascular invasion. The incidences
of early and/or multiple recurrence for HCC with major
vascular invasion was the highest in the four categories
of locally advanced HCC, while there were no significant
differences in the recurrence types among the remaining
three groups of patients. Similar results have also been
reported by Portolani et al [16]. In their series, major
vascular invasion correlated well with early and diffuse
recurrence which was rarely treatable, and thus an unsa-
tisfactory long-term survival. As multiple tumors can be
due to multicentric occurrence, they are likely to be
associated with a better prognosis [18,19]. The study by
Table 3 Univariate and multivariate Cox regression analyses for overall survival and cumulative recurrence rate
Univariate analysis Multivariate analysis
OS CRR OS CRR
Variable HR P HR P HR P HR P
Major vascular invasion* 3.500 <0.001 2.436 <0.001 3.291 <0.001 2.242 <0.001
ALB level † 0.601 0.004 0.541 0.002 0.693 0.094 0.689 0.066
Cirrhosis status ‡ 1.319 0.028 1.223 0.190 1.400 0.044 - -
OS, overall survival; CRR, cumulative recurrence rate; HR, hazard ratio.
* Major vascular invasion vs. No major vascular invasion.
† ALB > 35 g/L vs. <35 g/L.
‡ Cirrhosis vs. No cirrhosis.
Figure 1 Kaplan-Meier curves of overall survival and cumulative recurrence rates of four categories of locally advanced HCC patients .
Gp1, major vascular invasion (n = 21); Gp2, multiple tumors more than 5 cm (n = 108); Gp3, invasion of adjacent organs (n = 32); Gp4,
perforation of visceral peritoneum (n = 57). (A) Overall survival; Gp1 vs. Gp2, P < 0.001; Gp1 vs.Gp3, P = 0.001; Gp1 vs. Gp4, P < 0.001; Gp2 vs.
Gp3, P = 0.892; Gp2 vs. Gp4, P = 0.693; Gp3 vs. Gp4, P = 0.615. (B) Cumulative recurrence rate; Gp1 vs. Gp2, P = 0.006; Gp1 vs.Gp3, P = 0.001;
Gp1 vs. Gp4, P < 0.001; Gp2 vs. Gp3, P = 0.991; Gp2 vs. Gp4, P = 0.299; Gp3 vs. Gp4, P = 0.169.
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Poon et al. showed early recurrence within one year
after resection of HCC was more likely to be due to
metastasis than multicentric occurrence and was asso-
ciated with a worse prognosis when compared with late
recurrence [20]. Our results supported that patients
with HCC with major vascular invasion had a signifi-
cantly poorer prognosis than those with multiple tumors
more than 5 cm, those with invasion of adjacent organs,
or those with perforation of visceral peritoneum.
The prognosis of HCC is extremely poor in patients
with advanced disease [21]. For hepatic resection, the
presence of distant metastasis is generally considered a
contraindication [22]. In contrast, in view of the lack of
other effective treatment options, surgical resection
especially in eastern countries, is still advocated as the
treatment of choice for patients with locally advanced
HCC which is classified as pT3-4N0M0 [22-24]. Ishi-
zawa et al. demonstrated that partial hepatectomy pro-
vided survival benefits for patients with multiple tumors
with Child-Pugh class A cirrhosis [25]. For locally
advanced HCC, studies have also shown that survival
following hepatic resection compared favorably with
those treated non-surgically [10,11,26,27]. To improve
future survival rates, innovative multidisciplinary
approaches will also be needed. With recent advances in
adjuvant therapy such as immunotherapy and molecular
targeted therapy, whether these new modalities can
improve the prognosis of locally advanced HCC treated
with curative resection need to be clarified [28,29].
For patients with major vascular invasion, the prog-
nosis is particularly grave. Nonsurgical treatment with
systemic chemotherapy, intra-arterial chemotherapy, or
radiofrequency ablation for these patients results in dis-
mal 1-year survival rates, ranging from 7% to 18%
[30-32]. Patients with HCC and major vascular invasion
do not present technical contraindications to surgery.
However, results after hepatic resection for HCC with
major vascular invasion have been disappointing
[22,33,34]. In the current study, the median OS was
only 5.8 months after hepatic resection. Recently, the
Figure 2 Kaplan-Meier curves of overall survival and cumulative recurrence rates to compare vascular invasion with or without any of
the other pathologic features of locally advanced HCC patients . Gp1, major vascular invasion (n = 21); Gp5, multiple tumors more than 5
cm and major vascular invasion (n = 17); Gp6, invasion of adjacent organs and major vascular invasion (n = 10); Gp7, perforation of visceral
peritoneum and major vascular invasion (n = 13). (A) Overall survival; Gp1 vs. Gp5, P = 0.392; Gp1 vs.Gp6, P = 0.121; Gp1 vs. Gp7, P = 0.901; Gp5
vs. Gp6, P = 0.854; Gp5 vs. Gp7, P = 0.287; Gp6 vs. Gp7, P = 0.250. (B) Cumulative recurrence rate; Gp1 vs. Gp5, P = 0.914; Gp1 vs.Gp6, P = 0.909;
Gp1 vs. Gp7, P = 0.455; Gp5 vs. Gp6, P = 0.807; Gp5 vs. Gp7, P = 0.511; Gp6 vs. Gp7, P = 0.651.
Table 4 Recurrence types in four groups of locally advanced HCC
Recurrence time* No. of recurrence
Group Variables Cases Early(%) Late(%) P Single(%) Multiple(%) P
Gp1 Major vascular invasion only 21 19 (90.5) 2 (9.5) 3 (14.3) 18 (85.7)
Gp2 Multiple tumors more than 5 cm only 108 54 (58.7) 38 (41.3) 0.006 32 (34.8) 60 (65.2) 0.067
Gp3 Invasion of adjacent organs only 32 19 (65.5) 10 (34.5) 0.041 12 (41.4) 17 (58.6) 0.039
Gp4 Perforation of visceral peritoneum only 57 34 (64.2) 19 (35.8) 0.024 21 (39.6) 32 (60.4) 0.036
* Early recurrence, recurrence ≤ 12 months; late recurrence, recurrence > 12 months.
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efficacy of Sorafenib in patients with advanced HCC has
been evaluated in a randomized, double-blind, multicen-
tre, phase III trials: the SHARP (Sorafenib Hepatocellu-
lar Carcinoma Assessment Randomized Protocol) trial
[35]. However, the placebo group of the SHARP study
with similar baseline characteristics as in this study had
a median survival of 7.9 months. It seems that these
patients may not benefit from resection or even suffer
detrimental effects. Since there are no head-to-head stu-
dies comparing resection and nonsurgical treatment or
sorafenib in this category of patients, future studies will
need to investigate more thoroughly which modality
should be used as first line treatment.
There are several limitations of our study. Our study
is retrospective and it is based on a single-institutional
experience. The sample size of some of the subgroups is
relatively small. A larger scale, multi-center study is
needed to confirm our results.
Conclusion
In conclusion, our study suggested that the current 2002
TNM staging system failed to stratify patients with differ-
ent categories of locally advanced HCC according to the
outcomes after hepatic resection. The current pT3 sub-
group of major vascular invasion exhibited poor surgical
outcomes when compared with the other pT3 subgroups
with multiple tumors more than 5 cm, and the pT4
group with invasion of adjacent organs or perforation of
visceral peritoneum. These data, in addition to the pub-
lished data, challenge the value of the current 2002 TNM
staging classification in locally advanced HCC.
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